MedTrace Logo

Ceramide NanoLiposome in Patients With Advanced Solid Tumors

NCT02834611 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-05-29

No results posted yet for this study

Summary

This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.

Conditions

Interventions

DRUG

Ceramide NanoLiposome

Intravenous administration of Ceramide NanoLiposome

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Keystone Nano, Inc

    lead INDUSTRY

Principal Investigators

  • Edward Sausville, MD, PhD · University of Maryland Greenebaum Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-15
Primary Completion
2023-08-03
Completion
2023-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02834611 on ClinicalTrials.gov